Karen E. Knudsen, PhD

Contact Dr. Knudsen

Sidney Kimmel Cancer Center
233 South 10th Street
BLSB 1050
Philadelphia, PA 19107

(215) 503-5692

Most Recent Peer-reviewed Publications

  1. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  2. Differential impact of RB status on E2F1 reprogramming in human cancer
  3. Response and resistance to paradox-breaking BRAF inhibitor in melanomas in vivo and Ex vivo
  4. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells
  5. Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors
  6. Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors
  7. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
  8. PARP Inhibitors in Prostate Cancer
  9. Sigma1 targeting to suppress aberrant androgen receptor signaling in prostate cancer
  10. Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle
  11. Cell cycle-coupled expansion of AR activity promotes cancer progression
  12. RB loss promotes prostate cancer metastasis
  13. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  14. There and back again: The middle earth of DNA repair
  15. Linking DNA Damage and Hormone Signaling Pathways in Cancer
  16. Patient-level DNA damage and repair pathway profiles and prognosis after prostatectomy for high-risk prostate cancer
  17. Downregulation of critical oncogenes by the selective SK2 Inhibitor ABC294640 hinders prostate cancer progression
  18. Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors
  19. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- And tissue-specific microRNAs
  20. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer